YORK, Pennsylvania--GlaxoSmithKline and DENTSPLY International, a leader in professional dental products, have announced entering into an agreement to create a portfolio of co-branded oral care products for the dental office by patients who suffer from tooth sensitivity.To read more about tooth sensitivity, go to tooth sensitivity.Tooth sensitivity is a problem that is estimated to affect one in three people.In December 2009, GSK acquired NovaMin through the purchase of NovaMin Technology. NovaMin is a patent- protected calcium phosphate technology that has been clinically proven to relieve tooth sensitivity. The agreement, which involves no exchange of cash or equity from either party, will allow DENTSPLY to co-brand its NUPRO products that contain the NovaMin technology, with GSK's Sensodyne brand. This co-branding will provide a continuum of care for tooth sensitivity treatment from the dental office to everyday use at home."DENTSPLY and GSK have come together with one goal in mind--to provide a continuous treatment program for patients who suffer from the common problem of tooth sensitivity," remarked Christopher Clark, DENTSPLY's president and chief operating officer. "We are combining some of the most well-regarded brands and products on the market to provide a complete treatment solution with both in-office and at-home care regimens for patients suffering from this type of tooth pain. We are pleased to be partnering with GSK and Sensodyne, a global leader in sensitivity treatment."Added Carlton Lawson, vice president of Sensodyne, GSK: "This agreement demonstrates GSK Consumer Healthcare's strategy to grow and expand its science-driven oral health-care business. Through our agreement withDENTSPLY, sensitive teeth sufferers will be able to access an effective portfolio of Sensodyne-branded products providing continuous care from the dental office to the home. By leveraging both companies' brands andcapabilities, we aim to build awareness of the benefits of NovaMin and therefore further consolidate our position as the leader in the over the counter oral health-care market. DENTSPLY is a significant player and an important partner for us in the professional dental space, and we look forward to working closely with them to provideadditional sensitivity solutions in the future."The agreement also provides for the use of both companies' technical, clinical, and marketing resources to offer a comprehensive range of tooth sensitivity treatment options for the dental professional and the patient. While the agreement allows DENTSPLY to develop a portfolio of professional tooth sensitivity products, in the short term, DENTSPLY will release two, co-branded dental products containing the NovaMin(R) technology:* NUPRO Sensodyne Professional prophy paste: the proven performance of NUPRO powered by NovaMin, applied by dental professionals, to provide immediate in-office relief from tooth sensitivity * Sensodyne NUPRO Professional toothpaste: a toothpaste to be dispensed by dental professionals that contains NovaMin and high fluoride for enamel remineralizationFor more information of GSK, visit www.gsk.com.For more information on DENTSPLY, go to www.dentsply.com.To comment on this subject, go to community.pennwelldentalgroup.com/.